Objective
AIDS remains one of the major life threatening infectious diseases in the world today. A constant supply of novel antiretrovirals (ARVs) is needed to respond to the limitations of current drugs. By the end of 2007, the therapeutic arsenal against HIV is expected to comprise ARVs blocking all major steps of HIV replication, except for particle assembly and budding. Members of HIV-ACE were instrumental in recent breakthroughs concerning virus assembly and Envelope incorporation into virions. On the basis of novel and fully validated targets, the objectives of HIV-ACE are: i) Assay development, drug screening and pre-clinical development of small molecule inhibitors of Capsid assembly and Env incorporation, up to the stage of Early Drug Candidates with acceptable toxicity profile determined by ADME/Tox studies, activity against multi drug-resistant viral strains and primary non-B isolates, antiviral activity in primary T cells and macrophages (WP1); ii) Elucidation of 3D structures of these validated targets and rational drug design guided by molecular modelling and docking of inhibitors (WP2); iii) validation and exploitation of the HIV-susceptible transgenic rat model to allow preclinical in vivo-evaluation of novel drug candidates from HIV-ACE and to provide the European pharmaceutical industry with an efficient in vivo-platform for predictive testing of any kind of anti-HIV drug (WP3); iv) Elucidation of the mechanisms responsible for activity of the validated inhibitors, and discovery/validation of novel targets in the budding pathway of HIV-1 (WP4). HIV-ACE is composed of 8 teams from 5 European countries, including a Biopharma SME, led by prominent world-class scientists in Virology, Cell Biology, Immunology, Organic and Medicinal Chemistry, working in highly regarded research organisations. To efficiently achieve the ambitious goals of HIV-ACE, strong management led by a very experienced organisation has been included in a separate coordination-management WP5.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Call for proposal
FP7-HEALTH-2007-A
See other projects for this call
Funding Scheme
CP-FP - Small or medium-scale focused research projectCoordinator
75654 Paris
France